Cryopreserved Platelets (CPP) for US FDA Licensure
Subject: Cryopreserved Platelets (CPP) for US FDA LicensureSolicitation Number: HT9427-26-RFI-705Notice Type: SRCSGTNAICS: 541715Notice Published: 04-28-26Response Due: 05-04-26Agency: Other Defense AgenciesOffice: Defense Health AgencyContact: Peter Mitchell This email address is being protected from spambots. You need JavaScript enabled to view it.Office Address: FORT DETRICK, MD 21702Place of Performance: Frederick, MD 21702Related Notices:
Click for official SAM (FBO) notice, additional information, and accompanying attachments
Defense Health Agency seeks to develop and manage medical materiel to protect and sustain the Warfighter on point for the Nation. We develop, directly through collaboration with commercial partners, medical products that enhance readiness and improve the quality of life of active-duty personnel in the operational environment. OPMED’s WPAC PMO has been developing a biologic product: Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets (CPP), a frozen, biologic-platelet product. DMSO CPP are formulated to provide a platelet-derived product with a longer shelf life (2 years and potentially longer) than liquid stored platelets (LSP), which are currently licensed for storage up to 5-7 days at room temperature (20ºC to 24ºC) under gentle agitation.